CellPort is Attending Advanced Therapies Week

Advanced therapies continue to be a distinct area within the life science industry, shaped by cell- and gene-based work that unfolds across multiple stages rather than in isolated steps. Unlike more traditional development models, work in advanced therapies carries forward over time, with activities in development, production, and documentation remaining closely connected as programs progress.

‍

Because of this structure, continuity plays an important role. Information generated at earlier stages informs later work, records remain visible, and context is preserved as processes evolve. This interconnected nature influences how teams approach development, manufacturing, quality, and long-term program understanding across the lifecycle of an advanced therapy.

‍

Advanced Therapies Week provides a forum for the industry to engage with these realities. The event brings together organizations working across cell and gene therapy development to discuss shared challenges, evolving practices, and how work is carried forward in an increasingly complex landscape. Conversations at the conference reflect the structural characteristics of advanced therapies rather than focusing on any single solution or approach.

‍

Patrick Dentinger, CEO of CellPort, will be attending Advanced Therapies Week 2026 in San Diego to take part in these broader industry discussions and perspectives.